Portal Vein Thrombosis after Total Pancreatectomy and Islet Autotransplant: Prophylaxis and Graft Impact

Alexandria J. Robbins, Mariya E. Skube, Melena D. Bellin, Ty B. Dunn, Scott A. Chapman, K. Louise Berry, Elizabeth Lusczek, Gregory J. Beilman

Research output: Contribution to journalArticle

Abstract

Objectives To determine the rate of portal vein thrombosis (PVT) based on pharmacologic prophylaxis protocol and the impact of PVT on islet graft function after total pancreatectomy with islet autotransplantation (TPIAT). Methods We compared the incidence of PVT, postsurgical bleeding, and thrombotic complications in patients undergoing TPIAT between 2001 and 2018 at the University of Minnesota who received either unfractionated heparin (UFH) or enoxaparin for postoperative PVT prophylaxis. Six-month and 1-year graft function was compared between patients who developed PVT and those who did not. Results Twelve patients (6.6%) developed a PVT, which resolved by 6 months after TPIAT in 10 patients. There was no statistically significant difference in PVT rate between patients who received UFH or enoxaparin for prophylaxis (P = 0.54). Patients who received enoxaparin developed other thrombotic complications more often (6% vs 0%, P = 0.02). Islet graft function did not differ in patients who developed PVT versus those who did not. Conclusions There was no difference between enoxaparin or UFH prophylaxis in preventing PVT, but there may be a higher incidence of other thrombotic complications with enoxaparin. In the setting of routine screening and anticoagulation therapy, PVT is a self-limited process.

Original languageEnglish (US)
Pages (from-to)1329-1333
Number of pages5
JournalPancreas
Volume48
Issue number10
DOIs
StatePublished - Nov 1 2019

Fingerprint

Pancreatectomy
Autografts
Portal Vein
Thrombosis
Transplants
Enoxaparin
Autologous Transplantation
Heparin
Incidence
Hemorrhage

Keywords

  • TPIAT
  • anticoagulation
  • islet graft function
  • portal vein thrombosis

Cite this

Portal Vein Thrombosis after Total Pancreatectomy and Islet Autotransplant : Prophylaxis and Graft Impact. / Robbins, Alexandria J.; Skube, Mariya E.; Bellin, Melena D.; Dunn, Ty B.; Chapman, Scott A.; Berry, K. Louise; Lusczek, Elizabeth; Beilman, Gregory J.

In: Pancreas, Vol. 48, No. 10, 01.11.2019, p. 1329-1333.

Research output: Contribution to journalArticle

@article{afeec057016549ba993eb32c321ac376,
title = "Portal Vein Thrombosis after Total Pancreatectomy and Islet Autotransplant: Prophylaxis and Graft Impact",
abstract = "Objectives To determine the rate of portal vein thrombosis (PVT) based on pharmacologic prophylaxis protocol and the impact of PVT on islet graft function after total pancreatectomy with islet autotransplantation (TPIAT). Methods We compared the incidence of PVT, postsurgical bleeding, and thrombotic complications in patients undergoing TPIAT between 2001 and 2018 at the University of Minnesota who received either unfractionated heparin (UFH) or enoxaparin for postoperative PVT prophylaxis. Six-month and 1-year graft function was compared between patients who developed PVT and those who did not. Results Twelve patients (6.6{\%}) developed a PVT, which resolved by 6 months after TPIAT in 10 patients. There was no statistically significant difference in PVT rate between patients who received UFH or enoxaparin for prophylaxis (P = 0.54). Patients who received enoxaparin developed other thrombotic complications more often (6{\%} vs 0{\%}, P = 0.02). Islet graft function did not differ in patients who developed PVT versus those who did not. Conclusions There was no difference between enoxaparin or UFH prophylaxis in preventing PVT, but there may be a higher incidence of other thrombotic complications with enoxaparin. In the setting of routine screening and anticoagulation therapy, PVT is a self-limited process.",
keywords = "TPIAT, anticoagulation, islet graft function, portal vein thrombosis",
author = "Robbins, {Alexandria J.} and Skube, {Mariya E.} and Bellin, {Melena D.} and Dunn, {Ty B.} and Chapman, {Scott A.} and Berry, {K. Louise} and Elizabeth Lusczek and Beilman, {Gregory J.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1097/MPA.0000000000001421",
language = "English (US)",
volume = "48",
pages = "1329--1333",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Portal Vein Thrombosis after Total Pancreatectomy and Islet Autotransplant

T2 - Prophylaxis and Graft Impact

AU - Robbins, Alexandria J.

AU - Skube, Mariya E.

AU - Bellin, Melena D.

AU - Dunn, Ty B.

AU - Chapman, Scott A.

AU - Berry, K. Louise

AU - Lusczek, Elizabeth

AU - Beilman, Gregory J.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Objectives To determine the rate of portal vein thrombosis (PVT) based on pharmacologic prophylaxis protocol and the impact of PVT on islet graft function after total pancreatectomy with islet autotransplantation (TPIAT). Methods We compared the incidence of PVT, postsurgical bleeding, and thrombotic complications in patients undergoing TPIAT between 2001 and 2018 at the University of Minnesota who received either unfractionated heparin (UFH) or enoxaparin for postoperative PVT prophylaxis. Six-month and 1-year graft function was compared between patients who developed PVT and those who did not. Results Twelve patients (6.6%) developed a PVT, which resolved by 6 months after TPIAT in 10 patients. There was no statistically significant difference in PVT rate between patients who received UFH or enoxaparin for prophylaxis (P = 0.54). Patients who received enoxaparin developed other thrombotic complications more often (6% vs 0%, P = 0.02). Islet graft function did not differ in patients who developed PVT versus those who did not. Conclusions There was no difference between enoxaparin or UFH prophylaxis in preventing PVT, but there may be a higher incidence of other thrombotic complications with enoxaparin. In the setting of routine screening and anticoagulation therapy, PVT is a self-limited process.

AB - Objectives To determine the rate of portal vein thrombosis (PVT) based on pharmacologic prophylaxis protocol and the impact of PVT on islet graft function after total pancreatectomy with islet autotransplantation (TPIAT). Methods We compared the incidence of PVT, postsurgical bleeding, and thrombotic complications in patients undergoing TPIAT between 2001 and 2018 at the University of Minnesota who received either unfractionated heparin (UFH) or enoxaparin for postoperative PVT prophylaxis. Six-month and 1-year graft function was compared between patients who developed PVT and those who did not. Results Twelve patients (6.6%) developed a PVT, which resolved by 6 months after TPIAT in 10 patients. There was no statistically significant difference in PVT rate between patients who received UFH or enoxaparin for prophylaxis (P = 0.54). Patients who received enoxaparin developed other thrombotic complications more often (6% vs 0%, P = 0.02). Islet graft function did not differ in patients who developed PVT versus those who did not. Conclusions There was no difference between enoxaparin or UFH prophylaxis in preventing PVT, but there may be a higher incidence of other thrombotic complications with enoxaparin. In the setting of routine screening and anticoagulation therapy, PVT is a self-limited process.

KW - TPIAT

KW - anticoagulation

KW - islet graft function

KW - portal vein thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85074546053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074546053&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000001421

DO - 10.1097/MPA.0000000000001421

M3 - Article

C2 - 31688597

AN - SCOPUS:85074546053

VL - 48

SP - 1329

EP - 1333

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 10

ER -